{"nct_id":"NCT02453282","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2015-07-21","start_date_type":"ACTUAL","primary_completion_date":"2018-10-04","primary_completion_date_type":"ACTUAL","completion_date":"2025-12-31","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}